Jennifer McQuade, MD, MS, MA, LAc, discusses how age may serve as a predictor of response to neoadjuvant immunotherapy for patients with melanoma.
Jennifer McQuade, MD, MS, MA, LAc
Advertisement
Articles by Jennifer McQuade, MD, MS, MA, LAc
Advertisement
Latest Updated Articles
Dr. McQuade on Age as a Predictor of Response to Neoadjuvant Immunotherapy in MelanomaPublished: December 14th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5